With expansion a prime focus for businesses worldwide, many are looking towards rapidly establishing new regions of growth, particularly in Asia, Pacifi c Rim countries.
To appear in our next issue, send your Business and Financial News stories to
heather@intlabmate.com The latest business developments from across Europe & Middle East
by Heather Hobbs
This section of International Labmate will especially look at the success of both Asian and European companies with established premises or business partnerships, highlighting the opportunities that exist while realising potential for other companies to move into export markets.
GENE Consortium Appoints Analysis Partner
been sequenced and within its secure IT infrastructure, de-identifi ed data are being made available to Consortium participants to accelerate the development of new diagnostics and treatments for patients.
Since its formation in early 2014, Genomics plc has been building a powerful platform offering the tools to gain novel biological insights into the rich source of phenotypic data such as provided by Genomics England’s genetic information, which is increasingly linked to electronic medical records. It is also collaborating with major pharmaceutical companies including Biogen, Eisai, Merck and Vertex, as it applies its integrated platform across all areas of pharmaceutical R&D.
John Colenutt
Genomics plc has joined the Genomics England Genomics Expert Network for Enterprises (GENE) Consortium as an Analysis Partner to help uncover the relationships between genetic variation and human disease.
Genomics England is delivering the UK 100,000 Genomes Project – whole genome sequencing rare disease and cancer patients in the National Health Service. Set up in 2015, the GENE consortium, includes major pharmaceutical companies such as Abbvie, AstraZeneca, Biogen, GSK, Roche, Takeda and UCB. With a focus on patients with rare diseases and cancers, over 13,000 genomes have already
John Colenutt, CEO, Genomics plc, said: “We are excited to be working with Genomics England on the world-leading 100,000 Genomes Project. The use of human genetic data is increasingly recognised as a mechanism to transform productivity within the pharmaceutical and diagnostic research and development industry and we look forward to working with the GENE Consortium, its members and others within the sector to improve human health and reduce healthcare’s economic burden.”
Sir John Chisholm, Executive Chair, Genomics England, said: “The potential for genomics to transform healthcare, from better diagnoses to new drugs and treatments, is extraordinary and we are delighted to work with Genomics plc, a proven leader in the fi eld of genomic analysis, to maximise the value of the 100,000 Genomes Project for patients.”
40890pr@reply-direct.com
Oncovisions’s Preclinical PET Imaging Business
Moves to Bruker Bruker is to acquire the preclinical imaging business of Oncovision, a leading provider of medical imaging devices used for the diagnosis of cancer. For the past fi ve years, Bruker and Oncovision have held an exclusive marketing agreement for Albira™ PET/SPECT/CT systems, developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology and collaborated on a high-performance preclinical 3 Tesla SiPM-PET/MRI system.
Dr Wulf I. Jung, President of Bruker’s Preclinical Imaging Division, stated: “With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full fi eld of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations.”
As part of the agreement, Oncovision will retain its clinical human imaging business, including the MAMMI PET, a breast cancer diagnostic device based on PET imaging. A German-Spanish team of the law fi rm CMS acted as legal adviser to Bruker.
40888pr@reply-direct.com
Partnership to Develop Medicines for Protein Degradation
the labelling of these as ‘expired’ proteins, which the proteasome then removes.
“We believe our approach has the potential to fundamentally transform how we tackle protein targets to fi ght disease,” said Dr Ciulli, winner of the 2015 EFMC Prize for a young medicinal chemist in academia.
“We are very excited to partner with Boehringer Ingelheim, one of the world’s 20 leading pharmaceutical companies. This is a prime example of an industry-academia collaboration to establish a disruptive new approach to drug discovery, initially developed in academia and to enable its translation all the way to benefi t patients.”
The collaboration will also benefi t from top facilities and expertise available within the School of Life Sciences at Dundee, including the MRC Protein Phosphorylation and Ubiquitylation Unit, headed by Professor Dario Alessi, and the FingerPrint Proteomics Facility, co-directed by Professors Mike Ferguson and Angus Lamond and managed by Dr Douglas Lamont.
Dr Alessio Ciulli
The University of Dundee and Boehringer Ingelheim are collaborating to develop a novel class of medicines that target disease-causing proteins for degradation, using the expertise of the University’s Dr Alessio Ciulli, one of the pioneers in the fi eld of PROteolysis TArgeting Chimeric molecules (PROTACs).
PROTACs are designed to harness the cell’s natural disposal system (the ubiquitin-proteasome) to specifi cally remove disease-causing proteins. They do this by triggering
“We are looking forward to working with Dr Alessio Ciulli, one of the world leaders in this exciting new research area,” said Clive R. Wood, PhD, Senior Corporate Vice President, Discovery Research at Boehringer Ingelheim. “Working closely with the researchers at the University of Dundee, one of the top research centres in the UK for life sciences, we aim to establish a unique platform that can generate PROTAC-based drug candidates for multiple areas of unmet medical need.”
39855pr@reply-direct.com
Crescendo and Takeda Collaborate on Cancer
Therapeutics Development Drug discovery and developer Crescendo Biologics Therapeutics and Takeda Pharmaceutical Company have announced a global, strategic, multi-target collaboration and license agreement for the discovery, development and commercialisation of Humabody® -based therapeutics for cancer indications with a high unmet medical need.
Crescendo will use its proprietary transgenic platform and engineering expertise to discover and optimally confi gure Humabody® candidates (Humabody® Drug Conjugates and Immuno-Oncology modulators) against multiple targets selected by Takeda.
Under the terms of the agreement, Crescendo is eligible to receive up to $36 million, in a combination of an upfront payment, investment, research funding and preclinical milestones. Takeda will have the right to develop and commercialise Humabody®-based therapeutics resulting from the collaboration. Crescendo is also eligible to receive further clinical development, regulatory and sales-based milestone payments of up to $754 million. In addition, Crescendo will be eligible to receive royalties on Humabody®-based product sales by Takeda.
Takeda signed agreements with Crescendo Biologics through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.
40596pr@reply-direct.com
Business
Opportunities
Europe & Middle East
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44
